GLP1R and hyperlipidemia: “Diabetic conditions” – such as hyperglycemia and hyperlipidemia – can lead to the loss of the GLP-1 receptor (GLP-1R) from the cell surface and, thereby, impair GLP-1 signaling, which may underlie the reduced clinical efficacy of GLP-1R activators (50, 51).